C4 Therapeutics, Inc.
A biopharmaceutical company developing targeted protein degradation medicines, a technology that harnesses the body's own protein-disposal machinery to destroy disease-causing proteins. Its lead programs target cancers and other serious diseases. The company was founded in 2015 as a spinout from Dana-Farber Cancer Institute, and its name reflects its focus on the "C4" family of E3 ligase enzymes that tag proteins for destruction.
Granted 802.1K
Granted 16.6K
Granted 280.9K
Granted 270.9K · Sold 10.0K
Granted 266.3K
Granted 225.9K
Granted 225.9K
Granted 66.4K
Granted 19.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Hirsch AndrewPresident & CEO, Director · 5 transactions | +156.2% | 1.08M | 802.1K | — | — |
| Anderson Kenneth CarlDirector · 4 transactions | — | 525.4K | 16.6K | — | — |
| Adams KendraChief Financial Officer · 7 transactions | +136% | 400.5K | 280.9K | — | — |
| Reyno LeonardChief Medical Officer · 4 transactions | +128.1% | 396.4K | 270.9K | — | 10.0K |
| Mahaney PaigeChief Scientific Officer · 5 transactions | +220.9% | 336.9K | 266.3K | — | — |
| Boyle Scott NChief Business Officer · 5 transactions | +183.9% | 306.1K | 225.9K | — | — |
| Schick KellyChief People Officer · 5 transactions | +175.4% | 299.9K | 225.9K | — | — |
| Mossler MarkChief Accounting Officer · 3 transactions | +295.1% | 71.9K | 66.4K | — | — |
| Grogan Donna RoyDirector · 3 transactions | +37.8% | 71.5K | 19.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -10.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.